alluvi healthcare retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide, a new weight loss

In Q4 2024, US ZEPBOUND revenue reached USD 1.91 billion , a significant increase from USD 175.8 million in Q4 2023

[DOI] [PubMed] [Google Scholar] 98.Jensterle M., Salamun V., Kocjan T., Vrtacnik Bokal E., Janez A

Wegovy is a once weekly prescription medication containing semaglutide, which is used for chronic weight management in adults with obesity or overweight who also have weight-related health conditions, such as insulin resistance, high blood pressure, or high cholesterol

This represents a potentially significant advancement for treating fatty liver disease, which affects an estimated 25% of adults globally

The STEP4 study further confirmed the need to continue weekly therapy with semaglutide 2.4 mg in promoting long-term weight loss maintenance in people living with overweight/obesity, showing continued and persistent weight loss compared to participants transitioning to placebo and regaining body weight [150]